The same team is now launching a phase II study to test Probucol: https://pubmed.ncbi.nlm.nih.gov/35190446/ https://pubmed.ncbi.nlm.nih.gov/35190446/ "recent

The same team is now launching a phase II study to test Probucol: https://pubmed.ncbi.nlm.nih.gov/35190446/ https://pubmed.ncbi.nlm.nih.gov/35190446/ "recent studies suggest that increased plasma concentrations of lipoprotein-Aβ compromise the brain microvasculature, resulting in extravasation and retention of the lipoprotein-Aβ moiety. The latter results in an inflammatory response and neurodegeneration ensues. Probucol, a historic cholesterol-lowering drug, has been shown in murine models to suppress lipoprotein-Aβ secretion, concomitant with maintaining blood-brain-barrier function, suppressing neurovascular inflammation and supporting cognitive function."